State of Wisconsin Investment Board Has $801,000 Holdings in Neurocrine Biosciences, Inc. (NBIX)
State of Wisconsin Investment Board cut its position in Neurocrine Biosciences, Inc. (NASDAQ:NBIX) by 10.7% during the 2nd quarter, according to the company in its most recent disclosure with the SEC. The firm owned 17,412 shares of the company’s stock after selling 2,080 shares during the period. State of Wisconsin Investment Board’s holdings in Neurocrine Biosciences were worth $801,000 at the end of the most recent reporting period.
Other institutional investors and hedge funds have also recently bought and sold shares of the company. BB Biotech AG raised its holdings in Neurocrine Biosciences by 1.6% in the first quarter. BB Biotech AG now owns 3,201,552 shares of the company’s stock worth $138,627,000 after purchasing an additional 50,000 shares during the period. Teachers Advisors LLC raised its holdings in Neurocrine Biosciences by 6.3% in the fourth quarter. Teachers Advisors LLC now owns 78,287 shares of the company’s stock worth $3,030,000 after purchasing an additional 4,668 shares during the period. BlackRock Inc. raised its holdings in Neurocrine Biosciences by 14,216.0% in the first quarter. BlackRock Inc. now owns 5,031,933 shares of the company’s stock worth $217,884,000 after purchasing an additional 4,996,784 shares during the period. Airain ltd acquired a new stake in Neurocrine Biosciences in the first quarter worth $967,000. Finally, Point72 Asset Management L.P. acquired a new stake in Neurocrine Biosciences in the first quarter worth $4,330,000.
In related news, insider Haig P. Bozigian sold 26,250 shares of the stock in a transaction dated Wednesday, September 6th. The shares were sold at an average price of $60.00, for a total transaction of $1,575,000.00. Following the completion of the transaction, the insider now owns 144,601 shares in the company, valued at $8,676,060. The transaction was disclosed in a document filed with the SEC, which is available through this link. Also, insider Christopher Flint Obrien sold 8,734 shares of the stock in a transaction dated Thursday, July 27th. The shares were sold at an average price of $50.00, for a total transaction of $436,700.00. Following the transaction, the insider now owns 57,707 shares of the company’s stock, valued at approximately $2,885,350. The disclosure for this sale can be found here. In the last quarter, insiders sold 125,655 shares of company stock valued at $7,018,148. Company insiders own 4.80% of the company’s stock.
Several research firms have weighed in on NBIX. Cowen and Company reiterated an “outperform” rating and issued a $65.00 target price (up from $60.00) on shares of Neurocrine Biosciences in a report on Wednesday, August 9th. ValuEngine upgraded shares of Neurocrine Biosciences from a “sell” rating to a “hold” rating in a report on Friday, September 1st. Piper Jaffray Companies set a $68.00 target price on shares of Neurocrine Biosciences and gave the stock a “buy” rating in a report on Wednesday, May 24th. BMO Capital Markets increased their target price on shares of Neurocrine Biosciences from $75.00 to $84.00 and gave the stock an “outperform” rating in a report on Friday, August 4th. Finally, BidaskClub upgraded shares of Neurocrine Biosciences from a “hold” rating to a “buy” rating in a report on Wednesday, August 9th. Two investment analysts have rated the stock with a hold rating and seventeen have given a buy rating to the stock. The company currently has a consensus rating of “Buy” and an average price target of $68.25.
Shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX) opened at 57.74 on Friday. Neurocrine Biosciences, Inc. has a one year low of $37.35 and a one year high of $60.00. The firm’s market capitalization is $5.09 billion. The company’s 50 day moving average is $52.69 and its 200-day moving average is $48.43.
Neurocrine Biosciences (NASDAQ:NBIX) last released its quarterly earnings data on Thursday, August 3rd. The company reported ($0.68) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.67) by $0.01. The business had revenue of $6.34 million for the quarter, compared to analysts’ expectations of $0.61 million. During the same quarter last year, the firm posted ($0.46) EPS. Equities analysts expect that Neurocrine Biosciences, Inc. will post ($2.45) EPS for the current year.
Neurocrine Biosciences Profile
Neurocrine Biosciences, Inc is engaged in discovering and developing pharmaceuticals, in diseases with unmet medical needs, through its research and development (R&D) platform, focused on neurological and endocrine based diseases and disorders. Its three lead late-stage clinical programs are elagolix, which is a gonadotropin-releasing hormone (GnRH) antagonist for endometriosis and uterine fibroids; INGREZZA (valbenazine), which is a vesicular monoamine transporter 2 (VMAT2) inhibitor, for the treatment of movement disorders, and opicapone, which is a selective catechol-O-methyltransferase inhibitor that is an adjunct therapy to preparations of levodopa/Dihydroxyphenylalanine (DOPA) decarboxylase inhibitors for adult patients with Parkinson’s disease.
Receive News & Ratings for Neurocrine Biosciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neurocrine Biosciences Inc. and related companies with MarketBeat.com's FREE daily email newsletter.